

# ASX Announcement **29 February 2016**

### Taiwan FDA Approval and Maiden Contract Win

ITL Limited, the diversified healthcare company and owner of MyHealthTest, the provider of direct to consumer pathology testing, is pleased to report that after an 18 months process the Taiwan Food and Drug Administration, Ministry of Health and Welfare (TFDA) has approved its SampLok Sampling Kit (SSK) for sale in Taiwan.

This approval follows the recently announced grant of the SSK patent in the US and will help build the momentum of the Company's strategy to reach new markets around the world.

ITL BioMedical, a division of ITL also announces it has started supplying to its first Taiwan Blood Center and is being evaluated by additional blood centers.

SSK is used to transfer platelet samples when performing bacterial detection testing across the global blood banking market. SSK includes important safety features for lab personnel and is standard in many countries including the US and UK.

ITL BioMedical has a range of bacterial detection ancillaries as part of its wider portfolio of biological sampling and transfer kits. The division's products are distributed by industry leaders and partners around the world.

Bill Mobbs, Executive Chairman commented "This is a good achievement for ITL BioMedical. A very positive gain from the Taiwan approval is that together with the recently granted patent in the US it gives us confidence that SSK can grow sales in new markets around the globe."

**Bill Mobbs Executive Chairman** 

### ITL Limited ABN 16 088 212 088 Unit 1, 63 Wells Road Chelsea Heights, Victoria, 3196

ITL is an innovative diversified medical technology company that creates and manufactures leading edge medical devices for Operating Theatres, Bloodbanks and laboratories.

ITL's patented medical devices are sold in over 50 countries and protect healthcare workers in millions of procedures annually.

ITL's wholly owned subsidiary MyHealthTest creates and markets highly innovative direct to consumer pathology testing for major chronic diseases.

#### **Australian Securities Exchange**

Code: ITD

## **Ordinary Shares Board of Directors**

94.438.177

Bill Mobbs Executive Chairman Mark Peatey Non-executive Director Andrew Turnbull Non-executive Director

Trevor Doolan Company Secretary David Holden Chief Financial Officer

#### ITI Contact

Trevor Doolan Company Secretary Phone: +61 3 8773 3050 info@itl-limited.com

### www.itl-limited.com

### Media

Ben Knowles Walhrook IR Phone: +61 426 277 760 Email: ben.knowles@walbrookir.com.au